SAB3500420
Anti-RIPK1 antibody produced in rabbit
affinity isolated antibody, buffered aqueous solution
Synonym(s):
Anti-RIP, Anti-RIP1, Anti-Receptor-interacting serine/threonine-protein kinase 1
Sign Into View Organizational & Contract Pricing
All Photos(3)
About This Item
Recommended Products
biological source
rabbit
conjugate
unconjugated
antibody form
affinity isolated antibody
antibody product type
primary antibodies
clone
polyclonal
form
buffered aqueous solution
species reactivity
human, rat, mouse
technique(s)
immunofluorescence: suitable
immunohistochemistry: suitable
indirect ELISA: suitable
western blot: suitable
NCBI accession no.
UniProt accession no.
shipped in
dry ice
storage temp.
−20°C
target post-translational modification
unmodified
Gene Information
human ... RIPK1(8737)
Related Categories
General description
Receptor interacting serine/threonine kinase 1 (RIPK1) gene is located at 6p25.2 on the human chromosome. It belongs to the RIPK family. RIPK1 is a necroptosis regulatory protein. It is made up of N-terminal kinase domain, a RIP homotypic interaction motif and its C-terminal contains the death domain.
Immunogen
RIPK1 antibody was raised against a 15 amino acid peptide from near the amino terminus of human RIPK1.
Application
Anti-RIPK1 antibody produced in rabbit has been used in:
- western blotting
- immunocytochemistry
- immunofluorescence
Biochem/physiol Actions
Receptor interacting serine/threonine kinase 1 (RIPK1) is involved in inflammatory signaling and prosurvival. It is also involved in regulating the caspase-8-mediated apoptosis. RIPK1 plays a role in activating nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and mitogen-activated protein (MAP) kinases. Mutations in this gene is associated with impaired innate and adaptive immunity. It also leads to very early onset inflammatory bowel diseases (VEO-IBDs).
Receptor interacting serine/threonine kinase 1 (RIPK1) modulates cell survival and death. It also has a role in inflammation.
Features and Benefits
Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.
Linkage
The action of this antibody can be blocked using blocking peptide SBP3500420.
Physical form
Supplied in PBS with 0.02% sodium azide.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
Storage Class Code
10 - Combustible liquids
WGK
WGK 2
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Tauroursodeoxycholic acid protects nucleus pulposus cells from compression-induced apoptosis and necroptosis via inhibiting endoplasmic reticulum stress
Wang W, et al.
Evidence-Based Complementary and Alternative Medicine : ECAM, 2018(3), 493-499 (2018)
Human RIPK1 deficiency causes combined immunodeficiency and inflammatory bowel diseases
Li Y, et al.
Proceedings of the National Academy of Sciences, 116(3), 970-975 (2019)
Wenzheng Wang et al.
Evidence-based complementary and alternative medicine : eCAM, 2018, 6719460-6719460 (2018-05-04)
Tauroursodeoxycholic acid (TUDCA) is a kind of hydrophilic bile acid, which could protect cells from death via inhibiting endoplasmic reticulum (ER) stress. However, the role of TUDCA in compression-induced intervertebral disc degeneration (IVDD) has not been elucidated. Here, we used
Receptor interacting protein kinases-dependent necroptosis as a new, potent mechanism for elimination of the endothelial cells during luteolysis in cow
Hojo T, et al.
Theriogenology, 128(3), 193-200 (2019)
Nunzio Antonio Cacciola et al.
International journal of molecular sciences, 23(15) (2022-08-13)
Recent pharmacological research on milk whey, a byproduct of the dairy industry, has identified several therapeutic properties that could be exploited in modern medicine. In the present study, we investigated the anticancer effects of whey from Mediterranean buffalo (Bubalus bubalis)
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service